| Literature DB >> 32885157 |
Paolo Vincenzi1, Roberto Starnari2, Lucia Faloia2, Riccardo Grifoni1, Roberto Bucchianeri1, Leonardo Chiodi1, Alfredo Venezia2, Massimo Stronati2, Marina Giampieri2, Roberto Montalti3, Diletta Gaudenzi4, Lesley De Pietri5, Gianfranco Boccoli1.
Abstract
BACKGROUND: Limited studies have applied thoracic continuous spinal anesthesia in abdominal surgery, relying exclusively on opioids. This retrospective study analyzes 2 different schemes of thoracic continuous spinal anesthesia and postoperative analgesia in elderly patients undergoing major abdominal surgery.Entities:
Year: 2020 PMID: 32885157 PMCID: PMC7453121 DOI: 10.1016/j.sopen.2020.07.002
Source DB: PubMed Journal: Surg Open Sci ISSN: 2589-8450
Variables analyzed
| Demographics | Rate of conversion from TCSA to GA | Use of NE and maximum dose |
BMI, body mass index; HR, heart rate; NE, norepinephrine; SpO, pulse oximeter oxygen saturation.
Preoperative variables analyzed
| P | |||
|---|---|---|---|
| Age (y), mean ± SD | 84.4 ± 6.7 | 85.5 ± 6.1 | .411 |
| Male, | 19 (50) | 30 (50) | 1 |
| BMI (kg/m2), median (range) | 24 (17.6–45) | 22.8 (17–39) | .547 |
| Comorbidity, | |||
| Cardiac disease | 27 (71.1) | 38 (63.3) | .570 |
| Ischemic cardiac disease | 17 (62.9) | 22 (57.8) | .560 |
| CHF class II or III | 12 (44.4) | 18 (47.3) | .952 |
| COPD requiring LTOT | 17 (44.7) | 29 (48.3) | .888 |
| CNS disease | 10 (26.3) | 26 (43.3) | .137 |
| Stroke | 6 (60) | 16 (61.5) | .313 |
| Neurocognitive disorder | 3 (30) | 9 (34.6) | .466 |
| Parkinson disease | 2 (20) | 5 (19.2) | .863 |
| Complicated type 2 diabetes | 11 (28.9) | 18 (30) | 1 |
| Chronic renal failure | 12 (31.6) | 11 (18.3) | .815 |
| Charlson Comorbidity Index, mean ± SD | 7.5 ± 2.6 | 8 ± 2.6 | .414 |
| ASA score, | |||
| 2 | 2 (5.3) | 3 (5) | |
| 3 | 29 (76.3) | 40 (66.7) | .537 |
| 4 | 7 (18.4) | 17 (28.3) |
CHF, congestive heart failure; CNS, central nervous system; LTOT, long-term oxygen therapy.
Operative variables analyzed
| P | |||
|---|---|---|---|
| Surgical diagnosis, | |||
| Colorectal cancer | 16 (42.1) | 33 (55) | |
| Gastric cancer | 9 (23.7) | 7 (11.7) | |
| Non-neoplastic bowel obstruction | 4 (10.5) | 8 (13.3) | .265 |
| Gallbladder disease | 5 (13.2) | 3 (5) | |
| Other | 4 (10.5) | 9 (15) | |
| Urgency, | 13 (34.2) | 33 (55) | .072 |
| Surgical procedure, | |||
| Colectomy | 18 (47.4) | 39 (65) | |
| Gastrectomy | 9 (23.7) | 5 (8.3) | |
| Adhesiolysis | 4 (10.5) | 4 (6.7) | .053 |
| Cholecystectomy | 5 (13.2) | 3 (5) | |
| Other | 2 (5.3) | 9 (15) | |
| Operative time (min), mean ± SD | 126 ± 38 | 123 ± 45 | .672 |
| Relaparotomy, | 4 (10.5) | 8 (13.3) | .761 |
| Conversion to GA, | 0 (0) | 0 (0) | n.a. |
| Local anesthetics | |||
| Type, | 7 (18.4) | 37 (61.7) | <.001 |
| Hyperbaric bupivacaine | 35 (92.1) | 25 (41.7) | <.001 |
| Number (> 1), | 4 (10.5) | 2 (3.3) | .203 |
| Cumulative dose, median (range) | 9.5 (4–25) | 7.5 (5–15) | .034 |
| Hemodynamic | |||
| MAP, mean ± SD | 75.4 ± 7.1 | 72.8 ± 8.5 | .120 |
| HR, median (range) | 70 (55–92.5) | 75 (57.5–115) | .013 |
| SpO2, median (range) | 98 (92–100) | 97 (91.5–100) | .543 |
| Diuresis (mL/kg/h), mean ± SD | 0.96 ± 0.3 | 0.9 ± 0.3 | .373 |
| Fluid infusion (mL/kg/h), median (range) | 15.6 (6.6–33) | 18.6 (9–63.6) | .059 |
| Vasopressor support | |||
| NE use, | 27 (71.1) | 50 (83.3) | .243 |
| Max dose, | 0.09 (0.02–0.3) | 0.13 (0.04–0.59) | .048 |
| Pain with VAS > 4, | 0 | 0 | n.a. |
| Intravenous sedation, | 17 (44.7) | 57 (95) | <.001 |
| PRBCs, | 6 (15.8) | 14 (23.3) | .519 |
Complicated acute diverticulitis and ischemic colitis, ovarian neoplasm with abdominal compartmental syndrome, postincisional hernia, colostomy, perforated duodenal diverticulum, and enterocutaneous fistula.
With or without intestinal resection.
Hysterectomy with ovariosalpingectomy, laparoscopic repair of postincisional hernia, stoma reversal, internal bypass, and suture of duodenum.
Expressed in μg/kg/min.
Postoperative variables analyzed
| P | |||
|---|---|---|---|
| Vasopressor support | |||
| NE use, | 18 (47.4) | 44 (73.3) | .017 |
| Max dose, | 0.08 (0.01–0.24) | 0.12 (0.01–0.7) | .007 |
| Analgesia | |||
| Pain with VAS > 4, | 15 (39.5) | 23 (38.3) | 1 |
| VAS, mean ± SD | 6.24 ± 1.21 | 6.3 ± 1.09 | .840 |
| Intravenous analgesics, | 15 (39.5) | 23 (38.3) | 1 |
| Analgesic doses, | |||
| 1 | 8 (53.3) | 9 (39.1) | .598 |
| > 1 | 7 (46.7) | 14 (60.9) | |
| Need for mechanical ventilation, | 0 (0) | 0 (0) | n.a. |
| Respiratory depression, | 2 (5.2) | 14 (23.3) | .037 |
| Time to first flatus (p.o. day), median (range) | 2 (1–7) | 3 (1–7) | < .001 |
| Solid oral intake (p.o. day), median (range) | 5 (1–37) | 5 (1–12) | .686 |
| P.o. complications, | 32 (84.2) | 56 (93.3) | .179 |
| Clavien-Dindo grade, | |||
| I | 2 (6.2) | 0 | |
| II | 20 (62.5) | 37 (66.1) | |
| III | 2 (6.2) | 4 (7.1) | .218 |
| IV | 4 (12.5) | 3 (5.4) | |
| V | 4 (12.5) | 12 (21.4) | |
| CCI, median (range) | 30.2 (8.7–100) | 29.6 (20.9–100) | .359 |
| Anastomotic dehiscence, | 5 (17.9) | 6 (14) | .742 |
| Anemization, | 12 (31.6) | 23 (38.3) | .643 |
| Infections, | 10 (26.3) | 13 (21.7) | .776 |
| Acute respiratory failure, | 5 (13.2) | 14 (23.3) | .327 |
| Acute cardiac failure, | 4 (10.5) | 13 (21.7) | .252 |
| Arrhythmias (AFib/AF), | 4 (10.5) | 10 (16.7) | .582 |
| Acute kidney failure, | 2 (5.3) | 8 (13.3) | .308 |
| Headache, | 0 (0) | 0 (0) | n.a. |
| Other complications, | 8 (21.1) | 4 (6.7) | .055 |
| PRBC, | 12 (31.6) | 23 (38.3) | .643 |
| PRBC units, | 2.5 (1–9) | 2 (1–8) | .042 |
| Hospital stay (d), median (range) | 10 (3–49) | 12 (1–53) | .375 |
AF, atrial flutter; AFib, atrial fibrillation; CCI, comprehensive complication index; p.o., postoperative.
Expressed in μg/kg/min.
Calculated in patients with gastrointestinal anastomosis.
Requiring blood transfusions.
Acute urinary retention, PONV, acute hypertension, and transient ischemic attack.
Calculated in patients transfused.